Growth Metrics

Eli Lilly (LLY) Shares Outstanding (Weighted Average) (2016 - 2026)

Eli Lilly filings provide 18 years of Shares Outstanding (Weighted Average) readings, the most recent being $894.5 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed 0.47% to $894.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $894.5 million, a 0.47% change, with the full-year FY2025 number at $897.3 million, changed 0.37% from a year prior.
  • Shares Outstanding (Weighted Average) hit $894.5 million in Q1 2026 for Eli Lilly, roughly flat from $897.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $903.7 million in Q1 2022 to a low of $894.5 million in Q1 2026.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $900.6 million (2024), compared with a mean of $900.0 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): fell 0.68% in 2022 and later increased 0.13% in 2024.
  • Eli Lilly's Shares Outstanding (Weighted Average) stood at $901.7 million in 2022, then decreased by 0.17% to $900.2 million in 2023, then grew by 0.04% to $900.6 million in 2024, then fell by 0.37% to $897.3 million in 2025, then fell by 0.31% to $894.5 million in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $894.5 million (Q1 2026), $897.3 million (Q4 2025), and $897.8 million (Q3 2025) per Business Quant data.